Mass Vaccination Effort Targets Vulnerable Youth

An extensive vaccination program is set to offer the meningitis B (menB) vaccine to approximately one million young individuals. This initiative targets Year 13 pupils and those under 25 commencing university studies this autumn, aiming to bolster protection against the potentially fatal disease.

Two-Dose Protection Rollout

The one-off vaccination program will administer two doses of the menB vaccine. Eligible individuals aged 17 to 18 in Year 13, along with those under 25 embarking on university or other residential further education, will receive their first dose starting July 20. A second dose will be administered in August, with at least 28 days between vaccinations for optimal immunity.

Response to Recent Meningitis Outbreaks

This proactive measure follows a series of meningitis outbreaks, most notably a severe incident in Kent earlier this year that resulted in the deaths of two teenagers. The Kent outbreak was characterized as the fastest-growing and largest recorded in the UK. Since then, smaller clusters of meningitis among young people have also been more prevalent than anticipated. Close proximity and prolonged contact in settings like university halls, shared housing, and social gatherings are known to increase the risk of contracting menB.

Accessing the Vaccine

Year 13 pupils will be notified about their eligibility and appointment details via the NHS app, text messages, or letters. They will be offered the Bexsero vaccine, manufactured by GSK. Other eligible individuals under 25 can book their appointments directly with participating pharmacies. For those who might miss their August appointment due to holiday plans, arrangements are in place for them to receive the second dose in September. The vaccination program is being managed by community pharmacists.

Health Secretary’s Statement on Urgent Action

Health Secretary James Murray emphasized the urgency of the situation, stating, “The Kent outbreak and recent clusters indicate a possible change to the way menB affects people. While we assess the latest evidence, we are acting now to help protect young people at highest immediate risk as they enter university and residential colleges this autumn.”

He further elaborated on the program’s scope, noting it will be available to individuals completing Year 13 in the summer of 2026, born between September 1, 2007, and August 31, 2008, as well as those under 25 starting university or moving into certain residential further education settings in autumn 2026. “By offering two doses of the jabs ahead of the academic year, we will help reduce the risk of serious illness and larger outbreaks of this horrendous disease,” Murray added. “I urge all those students who are eligible to come forward for their two doses in July and August, to give them peace of mind as they head off to continue their studies.”

Understanding the Risk Factors

Analysis from the UK Health Security Agency (UKHSA) indicates that the risk of menB infection is significantly higher for first-year university students compared to their non-student peers. Invasive disease cases typically peak between October and November annually.

The government clarified that individuals completing Year 13 this summer, born within the specified 2007-2008 timeframe, are eligible regardless of their university plans. First-year university students under 25 are also included. However, students entering their second year or beyond, as well as postgraduate students, are not eligible for this specific program.

Ongoing Review and Expert Opinions

The Joint Committee on Vaccination and Immunisation (JCVI) is currently reviewing whether a more comprehensive and sustained vaccination program is necessary for young people.

When questioned about the exclusion of older university students, Dr. Shamez Ladhani, a consultant epidemiologist at UKHSA, explained, “The question about eligibility is always difficult, because you have to have boundaries to be able to deliver a programme, and at the moment, given how quickly we’ve had to work, we have had to prioritise those who are at highest risk.” He added, “The group that is being vaccinated is broadly the group at the highest risk. If you’re outside the eligibility, your risk is lower, and therefore it makes sense to protect those who are most needed first and then look at what we’re doing to try and see how best to optimise the programme.”

Dr. Ladhani suggested that a decline in population immunity against menB is the most likely reason for the recent increase in cases among young people. “The most likely explanation is that we actually have had 25 years of declining cases of menB disease,” he stated. “Now, meningococcal disease cycles go through cycles of 20 to 30 years. It goes down when you have good population immunity, and then that immunity goes down and new strains appear where the population doesn’t have immunity against these strains, and then cases start going up again.”

While acknowledging the potential role of COVID-19 lockdowns, Dr. Ladhani cautioned that definitively proving their impact is challenging. He noted a post-pandemic rise in meningitis cases that has since stabilized, but the extent of the pandemic’s contribution remains unclear.

Fatalities and Vaccine Efficacy

Dr. Thomas Waite, England’s deputy chief medical officer, highlighted that meningitis B can be fatal in up to 10% of cases. He urged, “Two doses of the menB vaccine, at least four weeks apart, are needed for maximum protection, and I encourage everyone who is attending university and further education for the first time this autumn to come forward for their first dose as soon as possible.”

The Department of Health advised that international students under 25 starting their first year of university should aim to receive their initial menB dose in their home countries if feasible.

Advocacy Groups Welcome Initiative

Charity leaders have responded positively to the announcement. Dr. Tom Nutt, chief executive of Meningitis Now, described the program as “a great step forward in the fight against meningitis in the UK.” He expressed a desire for wider and permanent rollout but acknowledged the current initiative as a “good practical and pragmatic response.”

Vinny Smith, chief executive of the Meningitis Research Foundation, viewed the program as “a step towards closing the UK’s menB protection gap.” However, he cautioned that “a one-off programme will not fully close that gap – teens and young adults who fall outside the current eligibility criteria remain at risk of menB. That is why we will continue to make the evidence-led case for routine NHS access for them, including seeking clarity from Government and the JCVI on what happens next.”